Safety and Efficacy of Pegvisomant in Pediatric Growth Hormone Excess

ABSTRACT: Abstract Objective: Pediatric growth hormone excess (GHE) and gigantism are mainly managed by pituitary surgery. However, a large percentage of patients require further medical management. Data for the pediatric population are scares and decisions are usually based on adult published data. We have initiated a study to investigate the efficacy and safety of pegvisomant in children and adolescents with GHE. MethodsThe study is registered in ClinicalTrials.gov (Identifier: NCT03882034, An open-label phase 3 study of the safety and efficacy of pegvisomant in children with growth hormone excess). Eligible patients must be children or adolescents (age: 24 months -18 years) with GHE with persistent disease after surgical or radiation therapy. The patients will receive pegvisomant via subcutaneous

SUBMITTER: Tatsi C 

PROVIDER: S-EPMC8090719 | biostudies-literature | 2021 May

REPOSITORIES: biostudies-literature